Literature DB >> 10208163

Genotype, molecular phenotype, and cognitive phenotype: correlations in fragile X syndrome.

W E Kaufmann1, M T Abrams, W Chen, A L Reiss.   

Abstract

The study of the neurobehavioral consequences of mutations of FMR1, the gene responsible for fragile X syndrome (FraX), has been based largely on correlations between mutation patterns and cognitive profile. Following the characterization of FMRP, the FMR1 gene product, preliminary correlations between FMRP levels, and neurologic phenotype have been established. However, most of these investigations have focused on individuals at both ends of the genetic and cognitive spectra of FraX, subjects with normal or premutation (PM) alleles or males with the FMR1 full mutation (FM). The present study is designed to characterize FMRP expression and to correlate it with IQ, in a sample representing a wide spectrum of FMR1 mutations. For this purpose we developed a highly sensitive immunoblotting assay using peripheral leukocytes. Three distinct patterns of FMRP immunoreactivity (-ir) emerged. Individuals with normal (n = 28) and PM (n = 8) alleles as well as most females with the FM (n = 14) showed the highest levels with multiple approximately 70-80 kDa FMRP-ir bands. Males with the FM (n = 10) demonstrated only a 70 kDa FMRP-ir band, and had significantly lower levels when compared with any previous groups. Males with mosaicism and three of 14 females with FM displayed a doublet with equal amounts of the highest and lowest molecular weight FMRP-ir bands. Multiple regression models that adjust for the effect of parental IQ indicated that both activation ratio and FMRP-ir are significantly correlated to subject IQ. We conclude that FMRP-ir offers promise as an indicator of the impact of FMR1 mutations upon neurologic function. Furthermore, our unexpected finding of FMRP-ir in all males with FM suggests that most of them are not transcriptionally silent.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10208163

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  42 in total

Review 1.  Epigenetics in nucleotide repeat expansion disorders.

Authors:  Fang He; Peter K Todd
Journal:  Semin Neurol       Date:  2012-01-21       Impact factor: 3.420

2.  Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome.

Authors:  F Tassone; R J Hagerman; A K Taylor; L W Gane; T E Godfrey; P J Hagerman
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

3.  The influence of apolipoprotein E genotype on visuospatial attention dissipates after age 80.

Authors:  Selam Negash; Pamela M Greenwood; Trey Sunderland; Raja Parasuraman; Yonas E Geda; David S Knopman; Bradley F Boeve; Robert J Ivnik; Ronald C Petersen; Glenn E Smith
Journal:  Neuropsychology       Date:  2009-01       Impact factor: 3.295

Review 4.  Insights into brain development from neurogenetic syndromes: evidence from fragile X syndrome, Williams syndrome, Turner syndrome and velocardiofacial syndrome.

Authors:  E Walter; P K Mazaika; A L Reiss
Journal:  Neuroscience       Date:  2009-04-17       Impact factor: 3.590

5.  FMR1 intron 1 methylation predicts FMRP expression in blood of female carriers of expanded FMR1 alleles.

Authors:  David E Godler; Howard R Slater; Quang M Bui; Michele Ono; Freya Gehling; David Francis; David J Amor; John L Hopper; Randi Hagerman; Danuta Z Loesch
Journal:  J Mol Diagn       Date:  2011-06-30       Impact factor: 5.568

6.  Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome.

Authors:  Alexia M Thomas; Nghiem Bui; Deanna Graham; Jennifer R Perkins; Lisa A Yuva-Paylor; Richard Paylor
Journal:  Behav Brain Res       Date:  2011-05-06       Impact factor: 3.332

7.  Motor deficits on a ladder rung task in male and female adolescent and adult CGG knock-in mice.

Authors:  Michael R Hunsaker; Ramona E von Leden; Binh T Ta; Naomi J Goodrich-Hunsaker; Gloria Arque; Kyoungmi Kim; Rob Willemsen; Robert F Berman
Journal:  Behav Brain Res       Date:  2011-03-31       Impact factor: 3.332

Review 8.  Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Authors:  Elizabeth M Berry-Kravis; Lothar Lindemann; Aia E Jønch; George Apostol; Mark F Bear; Randall L Carpenter; Jacqueline N Crawley; Aurore Curie; Vincent Des Portes; Farah Hossain; Fabrizio Gasparini; Baltazar Gomez-Mancilla; David Hessl; Eva Loth; Sebastian H Scharf; Paul P Wang; Florian Von Raison; Randi Hagerman; Will Spooren; Sébastien Jacquemont
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

9.  Impaired activity-dependent FMRP translation and enhanced mGluR-dependent LTD in Fragile X premutation mice.

Authors:  Adam J Iliff; Abigail J Renoux; Amy Krans; Karen Usdin; Michael A Sutton; Peter K Todd
Journal:  Hum Mol Genet       Date:  2012-12-18       Impact factor: 6.150

10.  Autism spectrum disorder in fragile X syndrome: a longitudinal evaluation.

Authors:  R Nick Hernandez; Rachel L Feinberg; Rebecca Vaurio; Natalie M Passanante; Richard E Thompson; Walter E Kaufmann
Journal:  Am J Med Genet A       Date:  2009-06       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.